Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

The company ended the third quarter of 2025 with $715 million in cash, a war chest deemed sufficient to fund both ongoing VANQUISH trials to completion. Research and development expenses jumped to $90 ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

The FDA has recalled thousands of Ziac blood pressure tablets after traces of a cholesterol drug were found during testing, ...

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many ...